Chemotherapy-Induced Neutropenia Treatment Market: Global Industry Analysis and Forecast (2024-2030)

The Global Chemotherapy-Induced Neutropenia Treatment Market size was valued at USD 539.86 Million in 2023 and the total Chemotherapy-Induced Neutropenia Treatment revenue is expected to grow at a CAGR of 3.8% from 2024 to 2030, reaching nearly USD 700.91 Million.

Chemotherapy-induced neutropenia (CIN) is a common side effect of chemotherapy treatment. Neutropenia refers to a decrease in the number of neutrophils, a type of white blood cell responsible for fighting off infections. Chemotherapy drugs suppress the bone marrow's ability to produce neutrophils, leading to a compromised immune system and increased susceptibility to infections. CIN results in delays or dose reductions in chemotherapy, impacting treatment efficacy. Patients with CIN are at a higher risk of developing infections, which are severe and require hospitalization. Thus, Chemotherapy-induced neutropenia requires careful monitoring and appropriate management to minimize complications and optimize the delivery of cancer treatment, thereby increasing the need for specific treatment therapies.

The increasing incidences of cancer all around the world have led to a higher number of patients undergoing chemotherapy, resulting in a greater demand for effective management of CIN. As a result, this factor is expected to be the major growth driver for the chemotherapy-induced neutropenia treatment market growth. Additionally, advancements in chemotherapy regimens, such as more potent and targeted therapies, have improved cancer treatment outcomes but have also increased the risk of CIN. This has driven the need for better strategies to prevent and manage neutropenia. However, high treatment costs, adverse effects, and limited awareness and education about CIN and its management are expected to pose restraints to market growth. Addressing these challenges and ensuring access to affordable and effective CIN treatments are important considerations in the market.

To know about the Research Methodology :- Request Free Sample Report
Chemotherapy-Induced Neutropenia Treatment Market Dynamics:
Increasing prevalence of Cancer across the world

The increasing incidence of cancer globally is a significant driver of the chemotherapy-induced neutropenia (CIN) treatment market. The rapidly growing aging population is a major factor in the increasing cancer incidence. The aging population increases cancer risk due to genetic mutations, weakened immune systems, cumulative exposure to carcinogens, altered DNA repair, hormonal changes, and age-related chronic conditions. Unhealthy lifestyle choices, such as tobacco use, sedentary lifestyles, poor diet, and excessive alcohol consumption, further contribute to the rising incidence of cancer. According to the MMR analysis, Cancer is a leading cause of mortality across the world, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths, including breast (2.26 million cases), lung (2.21 million cases), colon and rectum (1.93 million cases), prostate (1.41 million cases), skin (non-melanoma) (1.20 million cases), and stomach (1.09 million cases). Each year, approximately 400 000 children develop cancer.

As the incidence of cancer is on the rise, the demand for chemotherapy as a primary or adjunct treatment modality increases. Chemotherapy remains a cornerstone of cancer treatment and is often utilized in combination with other therapeutic approaches such as surgery, radiation therapy, targeted therapies, and immunotherapies. However, chemotherapy treatment carries the risk of chemotherapy-induced neutropenia (CIN), which is a common side effect. Thus, managing and mitigating the risk of CIN increases the demand for effective treatments and supportive care measures to manage CIN and reduce the associated complications, such as infections. The chemotherapy-induced neutropenia treatment industry responds to this demand by providing therapies and interventions to address the specific challenges posed by CIN in the context of increasing cancer incidence.Advancements in chemotherapy regimens increase the risk of CIN.

Advancements in chemotherapy regimens including the development of more potent and targeted therapies, have significantly improved the treatment outcomes for cancer patients, revolutionized cancer treatment by providing more effective and targeted therapies, and reduced side effects. Advancements in chemotherapy regimens include:

1. Targeted therapies: Designed to selectively attack cancer cells by targeting specific molecules or pathways, sparing healthy cells and reducing side effects.

2.  Immunotherapy: Uses drugs to stimulate the immune system's ability to recognize and destroy cancer cells, leading to improved survival rates and durable responses.

3. Combination therapies: Combining different chemotherapy drugs or combining chemotherapy with targeted therapies or immunotherapies to enhance treatment efficacy by attacking cancer cells through multiple mechanisms and overcoming resistance.

4.  Personalized medicine: Tailoring treatment strategies based on a patient's unique cancer characteristics, identified through genomic technologies and molecular profiling, to maximize treatment efficacy and minimize side effects.

These advancements continue to evolve rapidly, driven by ongoing research and technological innovations in the field of oncology. While these therapies offer better cancer treatment outcomes, they also increase the risk of CIN. The development of more potent chemotherapy drugs and the use of combination therapies affect the bone marrow's ability to produce an adequate number of neutrophils, leading to CIN. In addition, the risk of CIN is influenced by various factors, including the specific chemotherapy drugs used, their dosages, treatment schedules, and individual patient factors. Some chemotherapy drugs have a higher propensity to cause neutropenia than others. As a result, the need for effective management of CIN has led to the development of new treatment options, thus driving the chemotherapy-induced neutropenia treatment market growth.

High treatment cost

High treatment costs pose a significant restraining factor in the chemotherapy-induced neutropenia (CIN) treatment market. The cost of CIN treatments, such as colony-stimulating factors (CSFs), is expected to be substantial, especially in regions with limited healthcare coverage or high out-of-pocket expenses for patients. The financial burden of CIN treatments acts as a barrier to access for patients who may struggle to afford the costs. This lead to disparities in treatment availability and outcomes, particularly in regions where healthcare resources are limited or where patients have inadequate insurance coverage.

The high cost of CIN treatments also impacts patient compliance and adherence to treatment regimens. Some patients may be unable to consistently afford the necessary medications, resulting in suboptimal management of neutropenia and potentially compromising treatment outcomes. In addition to the direct costs of CIN treatments, there may be additional expenses associated with supportive care measures, such as infection prevention and management, which further contribute to the financial burden for patients.
Chemotherapy-Induced Neutropenia Treatment Market Segment Analysis:
Based on Treatment, the Growth Factors segment dominated the global chemotherapy-induced neutropenia treatment market growth with the highest revenue share in 2023. The segment is expected to grow at a CAGR of 4.1% and present lucrative growth prospects during the forecast period. Growth factors play a crucial role in managing and preventing neutropenia. The segment is further divided into Granulocyte Colony-Stimulating Factors (G-CSFs) and Granulocyte-Macrophage Colony-Stimulating Factors (GM-CSFs). Granulocyte Colony-Stimulating Factors (G-CSFs) therapy segment held the largest market share in the growth factors segment in 2023.

Granulocyte Colony-Stimulating Factor Therapy (G-CSF) is a widely used treatment for cancer-related neutropenia. This therapy is particularly prescribed for breast and lymphoma malignancies. One specific type of G-CSF therapy is filgrastim, which is a recombinant human granulocyte colony-stimulating factor. It works by stimulating the production of neutrophilic granulocytes in patients undergoing chemotherapy, thereby helping to prevent or manage chemotherapy-induced neutropenia and febrile neutropenia.

In a publication from the National Center for Biotechnology Information in 2020, titled "Supportive care in patients with cancer during the COVID-19 pandemic," it was noted that prophylactic G-CSF therapy has been found to be effective in reducing the risk of neutropenia in cancer patients undergoing chemotherapy. The article emphasized that this treatment approach is particularly relevant during the COVID-19 pandemic, as cancer patients are more susceptible to severe infections, including those caused by the virus. The use of prophylactic granulocyte colony-stimulating factor (G-CSF) in cancer patients with chemotherapy has a low or intermediate risk of developing neutropenia in patients.

As a result, the rising prevalence of cancer patients increases the need for chemotherapy treatment which is further expected to increase the demand for granulocyte colony-stimulating factor therapy to reduce the risks of developing neutropenia. Thus, these factors are expected to support the segment growth during the forecast period.

In addition, the increasing company focus on developing granulocyte colony-stimulating factor therapy drugs for treating chemotherapy-induced neutropenia in cancer patients through various business strategies such as new product launches, agreements, mergers, and collaboration are also contributing to the chemotherapy-induced neutropenia treatment industry growth over the forecast period. For instance,

1. In February 2022, Lupin, a pharmaceutical company, entered into a license, supply, and technology-sharing agreement with Axantia. As part of this agreement, Axantia assumes responsibility for the registration, distribution, and marketing of biosimilar Pegfilgrastim drug products in specific territories, including Saudi Arabia, certain GCC countries, Jordan, Lebanon, Iraq, Sudan, Libya, and Algeria. This collaboration enables the introduction of biosimilar Pegfilgrastim drugs into these markets, providing cancer patients with access to an affordable and effective treatment option for chemotherapy-induced neutropenia.

As a result, through strategic partnerships, agreements, and expansion into new territories, these companies are contributing to the growth and availability of G-CSF therapies, ultimately enhancing supportive care for cancer patients.
Chemotherapy-Induced Neutropenia Treatment Market Regional Insights:
North America led the global chemotherapy-induced neutropenia treatment market with the highest market share of 37.8% in 2023. The region is further expected to grow at a CAGR of 3.5% and maintain its dominance by 2030. The increasing prevalence of cancer cases and widespread use of chemotherapy is expected to be the major growth factor driving the North American chemotherapy-induced neutropenia treatment market growth. According to the MMR analysis, in 2022, the United States is expected to have 1,918,030 new cancer cases and 609,360 cancer deaths, with lung cancer, the primary cause of cancer mortality, accounting for nearly 350 fatalities each day.

From 2014 to 2018, the incidence of female breast cancer increased slowly (by 0.5% per year) whereas prostate cancer remained steady, despite a 4% to 6% yearly increase in the advanced illness since 2011. As a result, the proportion of prostate cancer identified at a later stage has risen from 3.9% to 8.2% in the last decade. In contrast, lung cancer incidence for advanced disease continued to fall sharply, while rates for localized-stage disease increased abruptly by 4.5% per year, contributing to increases in both the proportion of localized-stage diagnoses (from 17% in 2004 to 28% in 2018) and 3-year relative survival (from 21% to 31%).
Estimated New Cancer Cases and Deaths by Sex, United States, 2022In addition, according to an article published in 2021 by the National Centre for Biotechnology Information titled "Chemotherapy-Induced Neutropenia Burden in Cancer Patients," chemotherapy-induced neutropenia continues to be a significant burden on cancer patients in terms of hospitalization and mortality, as well as on healthcare systems in terms of expense, in the United States. Besides that, the growing need for disease-specific treatment, increased healthcare spending, and well-established healthcare infrastructure, and the presence of the market players such as Amgen Inc., Pfizer Inc., and Eli Lilly and Company in the region is expected to further drive the chemotherapy-induced neutropenia treatment market growth during the forecast period.

The growing focus on manufacturing advanced and efficient therapies for treating chemotherapy-induced neutropenia by major key players and increasing drug approvals is also contributing to the regional market growth. For instance,

1. In June 2021, BeyondSpring Inc. submitted a new drug application, including a priority review request, to the United States Food and Drug Administration for plinabulin combined with granulocyte colony-stimulating factor (G-CSF) as a preventive treatment for chemotherapy-induced neutropenia (CIN).

2. In September 2020, Pinabulin was granted breakthrough therapy designation by the FDA in the United States and China's Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), recognizing its potential as an important therapy for a specific medical condition.

As a result, the increasing prevalence of cancer, rising chemotherapy treatment options, increasing company focus on innovative drug and treatment products, and increasing research and development expenditures in the region are expected to boost the North American chemotherapy-induced neutropenia treatment market growth during the forecast period.

The Asia Pacific region is expected to grow at a significant CAGR and presents lucrative growth opportunities for the market players during the forecast period. Rising incidences of cancers, increasing access to healthcare, and improving awareness about supportive care are expected to be the primary growth factors driving the regional market growth. In addition, Local pharmaceutical companies, such as Sun Pharmaceutical Industries Ltd. (India) and Celltrion Inc. (South Korea), are actively involved in developing and supplying treatment options, supporting the Asia Pacific chemotherapy-induced neutropenia treatment market growth. Countries including China, India, Japan, and South Korea are expected to be the major contributors to the market growth in this region.

Besides that, increasing medical tourism is further expected to be the key factor driving the chemotherapy-induced neutropenia treatment market in the APAC region. The Asia-Pacific Medical Tourism Market is a rapidly expanding industry characterized by individuals traveling to foreign countries for medical treatment. Countries such as Thailand, India, Malaysia, Singapore, and South Korea are prominent destinations known for their high-quality healthcare services and competitive treatment costs. In addition, the rising healthcare expenses in developed countries, increased awareness of medical treatment options abroad, and advancements in medical technologies are further factors driving the industry revenue. Government initiatives supporting medical tourism, including streamlined visa processes and incentives for healthcare providers, have further propelled market growth. The region is gaining popularity for complex procedures like cancer treatments. Thus, increasing medical tourism necessitates the need for advanced treatments for cancer, thereby supporting the chemotherapy-induced neutropenia treatment market growth.
Chemotherapy-Induced Neutropenia Treatment Market Scope: Inquire before buying



Chemotherapy-Induced Neutropenia Treatment Market


Report Coverage
Details


Base Year:
2023
Forecast Period:
2024-2030


Historical Data:
2018 to 2023
Market Size in 2023:
USD 539.86 Mn.


Forecast Period 2024 to 2030 CAGR:
3.8%
Market Size in 2030:
USD 700.91 Mn.


 Segments Covered:
by Treatment
1.Growth Factors
1.1.Granulocyte Colony-Stimulating Factors (G-CSFs)
1.2.Granulocyte-Macrophage Colony-Stimulating Factors (GM-CSFs)
2.Antibiotics
2.1.Prophylactic Antibiotics
2.2.Others
3.Antifungal Agents
3.1.Prophylactic Antifungal Agents
3.2.Others



by Distribution Channel
1.Hospital Pharmacies
2.Specialty Clinics
3.Retail Pharmacies
4.Online Pharmacies



Chemotherapy-Induced Neutropenia Treatment Market, by Region
North America (United States, Canada, and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, and the Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan, and the Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria, and the Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Chemotherapy-Induced Neutropenia Treatment Market, Key Players:
1.Amgen Inc. (United States)
2.Sanofi S.A. (France)
3. Novartis AG (Switzerland)
4.Pfizer Inc. (United States)
5.Teva Pharmaceutical Industries Ltd. (Israel)
6.Amneal Pharmaceuticals LLC. (United States)
7. Mylan N.V. (United States)
8.Apotex Inc. (Canada)
9. Biocon Ltd. (India)
10.Coherus BioSciences, Inc. (United States)
11. Celltrion Inc. (South Korea)
12. Dr. Reddy's Laboratories Ltd. (India)
13.Hospira Inc. (a Pfizer company) (United States)
14.Merck & Co., Inc. (United States)
15. Eli Lilly and Company (United States)
16.Accord Healthcare Ltd. (United Kingdom)
17. Baxter International Inc. (United States)
18.Gilead Sciences, Inc. (United States)
19.Glenmark Pharmaceuticals Ltd. (India)
20.Sun Pharmaceutical Industries Ltd. (India)
21. Spectrum Pharmaceuticals (United States)
22.Kyowa Hakko Kirin Co., Ltd. (Japan)
23.G1 Therapeutics (United States)
24. Enzychem Lifesciences Corporation (South Korea)
25.Novartis AG (Switzerland)
26.BeyondSpring Pharmaceuticals Inc. (New York)
27. Hanmi Pharmaceuticals Co. Ltd. (South Korea)

FAQs:

1] What are the growth drivers for the Chemotherapy-Induced Neutropenia Treatment market?
Ans. The increasing prevalence of cancer is expected to be the major driver for the Chemotherapy-Induced Neutropenia Treatment market.

2] What is the major restraint on the Chemotherapy-Induced Neutropenia Treatment market growth?
Ans. High treatment costs, adverse effects of CIN treatments, Lack of awareness and education, etc. are expected to be the major restraining factor for the Chemotherapy-Induced Neutropenia Treatment market growth.

3] Which region is expected to lead the global Chemotherapy-Induced Neutropenia Treatment market during the forecast period?
Ans. North America is expected to lead the global Chemotherapy-Induced Neutropenia Treatment market during the forecast period.

4] What is the projected market size & growth rate of the Chemotherapy-Induced Neutropenia Treatment Market?
Ans. The Global Chemotherapy-Induced Neutropenia Treatment Market size was valued at USD 539.86 Million in 2023 and the total Chemotherapy-Induced Neutropenia Treatment revenue is expected to grow at a CAGR of 3.8% from 2024 to 2030, reaching nearly USD 700.91 Million.

5] What segments are covered in the Chemotherapy-Induced Neutropenia Treatment Market report?
Ans. The segments covered in the Chemotherapy-Induced Neutropenia Treatment market report are Treatment, Distribution Channel, and Region.